Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

Marco Montillo; Alessandra Tedeschi; Gianluca Gaidano; Marta Coscia; Valeria Belsito Petrizzi; Ester Orlandi; Nicola Cascavilla; Paolo Ghia; Marina Motta; Andrea Gallamini; Anna Maria Frustaci; Davide Rossi; Lorenzo De Paoli; Michele Nichelatti; Enrica Morra; Massimo Massaia

doi:10.3324/haematol.2014.106740

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

Marco Montillo, Alessandra Tedeschi, Gianluca Gaidano, Marta Coscia, Valeria Belsito Petrizzi, Ester Orlandi, Nicola Cascavilla, Paolo Ghia, Marina Motta, Andrea Gallamini, Anna Maria Frustaci, Davide Rossi, Lorenzo De Paoli, Michele Nichelatti, Enrica Morra, Massimo Massaia

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Haematologica
Volume	99
Issue number	9
DOIs	https://doi.org/10.3324/haematol.2014.106740
Publication status	Published - Sep 1 2014

Keywords

Bendamustine
Effective treatment
Relapsed/refractory chronic lymphocytic leukemia

ASJC Scopus subject areas

Hematology
Medicine(all)

Access to Document

10.3324/haematol.2014.106740

Cite this

Montillo, M., Tedeschi, A., Gaidano, G., Coscia, M., Petrizzi, V. B., Orlandi, E., Cascavilla, N., Ghia, P., Motta, M., Gallamini, A., Frustaci, A. M., Rossi, D., De Paoli, L., Nichelatti, M., Morra, E., & Massaia, M. (2014). Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. Haematologica, 99(9). https://doi.org/10.3324/haematol.2014.106740

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. / Montillo, Marco; Tedeschi, Alessandra; Gaidano, Gianluca; Coscia, Marta; Petrizzi, Valeria Belsito; Orlandi, Ester; Cascavilla, Nicola; Ghia, Paolo; Motta, Marina; Gallamini, Andrea; Frustaci, Anna Maria; Rossi, Davide; De Paoli, Lorenzo; Nichelatti, Michele; Morra, Enrica; Massaia, Massimo.

In: Haematologica, Vol. 99, No. 9, 01.09.2014.

Research output: Contribution to journal › Article › peer-review

Montillo, M, Tedeschi, A, Gaidano, G, Coscia, M, Petrizzi, VB, Orlandi, E, Cascavilla, N, Ghia, P, Motta, M, Gallamini, A, Frustaci, AM, Rossi, D, De Paoli, L, Nichelatti, M, Morra, E & Massaia, M 2014, 'Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients', Haematologica, vol. 99, no. 9. https://doi.org/10.3324/haematol.2014.106740

Montillo, Marco ; Tedeschi, Alessandra ; Gaidano, Gianluca ; Coscia, Marta ; Petrizzi, Valeria Belsito ; Orlandi, Ester ; Cascavilla, Nicola ; Ghia, Paolo ; Motta, Marina ; Gallamini, Andrea ; Frustaci, Anna Maria ; Rossi, Davide ; De Paoli, Lorenzo ; Nichelatti, Michele ; Morra, Enrica ; Massaia, Massimo. / Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. In: Haematologica. 2014 ; Vol. 99, No. 9.

@article{b85f81234aa645b4a00c2146e8273ff9,

title = "Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients",

keywords = "Bendamustine, Effective treatment, Relapsed/refractory chronic lymphocytic leukemia",

author = "Marco Montillo and Alessandra Tedeschi and Gianluca Gaidano and Marta Coscia and Petrizzi, {Valeria Belsito} and Ester Orlandi and Nicola Cascavilla and Paolo Ghia and Marina Motta and Andrea Gallamini and Frustaci, {Anna Maria} and Davide Rossi and {De Paoli}, Lorenzo and Michele Nichelatti and Enrica Morra and Massimo Massaia",

year = "2014",

month = sep,

day = "1",

doi = "10.3324/haematol.2014.106740",

language = "English",

volume = "99",

journal = "Haematologica",

issn = "0390-6078",

publisher = "NLM (Medline)",

number = "9",

}

TY - JOUR

T1 - Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

AU - Montillo, Marco

AU - Tedeschi, Alessandra

AU - Gaidano, Gianluca

AU - Coscia, Marta

AU - Petrizzi, Valeria Belsito

AU - Orlandi, Ester

AU - Cascavilla, Nicola

AU - Ghia, Paolo

AU - Motta, Marina

AU - Gallamini, Andrea

AU - Frustaci, Anna Maria

AU - Rossi, Davide

AU - De Paoli, Lorenzo

AU - Nichelatti, Michele

AU - Morra, Enrica

AU - Massaia, Massimo

PY - 2014/9/1

Y1 - 2014/9/1

KW - Bendamustine

KW - Effective treatment

KW - Relapsed/refractory chronic lymphocytic leukemia

UR - http://www.scopus.com/inward/record.url?scp=84907374559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907374559&partnerID=8YFLogxK

U2 - 10.3324/haematol.2014.106740

DO - 10.3324/haematol.2014.106740

M3 - Article

C2 - 24972768

AN - SCOPUS:84907374559

VL - 99

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 9

ER -

Bendamustine and subcutaneous alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this